Osimertinib‐related liver injury with successful osimertinib rechallenge: A case report

Osimertinib is approved as the first‐line treatment for advanced non‐small cell lung cancer patients with epidermal growth factor (EGFR) mutation and for patients who develop EGFR T790M mutation during EGFR tyrosine kinase inhibitor (TKI) treatment and disease progression. Asymptomatic elevation of...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Yuan‐Ling, Chang, Wei‐Kuo, Yen, Hao, Peng, Yi‐Jen, Chang, Wei‐Chou, Chang, Ping‐Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346189/
https://www.ncbi.nlm.nih.gov/pubmed/35793806
http://dx.doi.org/10.1111/1759-7714.14556
_version_ 1784761594170834944
author Cheng, Yuan‐Ling
Chang, Wei‐Kuo
Yen, Hao
Peng, Yi‐Jen
Chang, Wei‐Chou
Chang, Ping‐Ying
author_facet Cheng, Yuan‐Ling
Chang, Wei‐Kuo
Yen, Hao
Peng, Yi‐Jen
Chang, Wei‐Chou
Chang, Ping‐Ying
author_sort Cheng, Yuan‐Ling
collection PubMed
description Osimertinib is approved as the first‐line treatment for advanced non‐small cell lung cancer patients with epidermal growth factor (EGFR) mutation and for patients who develop EGFR T790M mutation during EGFR tyrosine kinase inhibitor (TKI) treatment and disease progression. Asymptomatic elevation of aminotransferase levels is commonly observed during TKI treatment; however, significant hepatotoxicity is infrequent. Here, we report a patient with osimertinib‐related drug‐induced liver injury who was successfully managed with osimertinib rechallenge.
format Online
Article
Text
id pubmed-9346189
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-93461892022-08-05 Osimertinib‐related liver injury with successful osimertinib rechallenge: A case report Cheng, Yuan‐Ling Chang, Wei‐Kuo Yen, Hao Peng, Yi‐Jen Chang, Wei‐Chou Chang, Ping‐Ying Thorac Cancer Case Reports Osimertinib is approved as the first‐line treatment for advanced non‐small cell lung cancer patients with epidermal growth factor (EGFR) mutation and for patients who develop EGFR T790M mutation during EGFR tyrosine kinase inhibitor (TKI) treatment and disease progression. Asymptomatic elevation of aminotransferase levels is commonly observed during TKI treatment; however, significant hepatotoxicity is infrequent. Here, we report a patient with osimertinib‐related drug‐induced liver injury who was successfully managed with osimertinib rechallenge. John Wiley & Sons Australia, Ltd 2022-07-06 2022-08 /pmc/articles/PMC9346189/ /pubmed/35793806 http://dx.doi.org/10.1111/1759-7714.14556 Text en © 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Cheng, Yuan‐Ling
Chang, Wei‐Kuo
Yen, Hao
Peng, Yi‐Jen
Chang, Wei‐Chou
Chang, Ping‐Ying
Osimertinib‐related liver injury with successful osimertinib rechallenge: A case report
title Osimertinib‐related liver injury with successful osimertinib rechallenge: A case report
title_full Osimertinib‐related liver injury with successful osimertinib rechallenge: A case report
title_fullStr Osimertinib‐related liver injury with successful osimertinib rechallenge: A case report
title_full_unstemmed Osimertinib‐related liver injury with successful osimertinib rechallenge: A case report
title_short Osimertinib‐related liver injury with successful osimertinib rechallenge: A case report
title_sort osimertinib‐related liver injury with successful osimertinib rechallenge: a case report
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346189/
https://www.ncbi.nlm.nih.gov/pubmed/35793806
http://dx.doi.org/10.1111/1759-7714.14556
work_keys_str_mv AT chengyuanling osimertinibrelatedliverinjurywithsuccessfulosimertinibrechallengeacasereport
AT changweikuo osimertinibrelatedliverinjurywithsuccessfulosimertinibrechallengeacasereport
AT yenhao osimertinibrelatedliverinjurywithsuccessfulosimertinibrechallengeacasereport
AT pengyijen osimertinibrelatedliverinjurywithsuccessfulosimertinibrechallengeacasereport
AT changweichou osimertinibrelatedliverinjurywithsuccessfulosimertinibrechallengeacasereport
AT changpingying osimertinibrelatedliverinjurywithsuccessfulosimertinibrechallengeacasereport

Ejemplares similares